|
|
Vaccine Detail
|
UK39 |
| Vaccine Information |
- Vaccine Name: UK39
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Virosome-formulated synthetic peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: UK39: a circumsporozoite protein (CSP) derived synthetic PE-peptide conjugate (Genton et al., 2007)
- CSP from P. falciparum
gene engineering:
- Type: Conjugate vaccine preparation
- Description: UK39 is a circumsporozoite protein (CSP) derived synthetic PE-peptide conjugate (Genton et al., 2007)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: UK39 is a virosome-formulated P. falciparum circumsporozoit protien (CSP) derived synthetic peptide antigen that serves as a malaria vaccine (Genton et al., 2003)
|
| Host Response |
|
Baboon Response
- Host Strain: healthy Caucasian volunteers aged 18-45 years
- Immune Response: Mean titer and seroconversion rate were higher with the 10ug dose than the 50 ug dose. (Genton et al., 2003)
|
| References |
Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].
Genton et al., 2007: Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PloS one. 2007; 2(10); e1018. [PubMed: 17925866].
|
|
